idenix pharmaceuticals inc
Transactions by IDENIX PHARMACEUTICALS INC (NO9) in the last 6 months
Merck & Co. Inc. (NYSE:MRK) entered into a definitive agreement to acquire Idenix Pharmaceuticals Inc. (NasdaqGS:IDIX) from T. Rowe Price Associates, Inc., Nomura International plc, Brookside Capital Management, LLC, The Baupost Group, LLC and other shareholders for $3.84 billion in cash on June 8, 2014. Under the terms of the agreement, Merck will pay $24.5 per share. Under the terms of the agreement, Merck, through a subsidiary, will initiate a tender offer to acquire ...
|No competitor information is available for NO9.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|